SCHEMBL3954982

SCHEMBL3954982

COc1ccnc2[nH]c(C3CCC3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 2/20 0.40
▸ PDE4B Q07343 2/20 0.40
▸ PDE4C Q08493 2/20 0.40
▸ PDE4D Q08499 2/20 0.40
▸ CDK9 P50750 13/20 0.40
▸ CCNT1 O60563 12/20 0.40
▸ ADORA3 P0DMS8 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ CDK1 P06493 3/20 0.38
▸ CCNB1 P14635 2/20 0.38
▸ CDK4 P11802 1/20 0.38
▸ CCND1 P24385 1/20 0.38
▸ CCNE1 P24864 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ NOS1 P29475 1/20 0.37
▸ NOS2 P35228 1/20 0.37
▸ CCNB2 O95067 1/20 0.36
▸ GSK3A P49840 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ CCNB3 Q8WWL7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3949386 0.81 BRD4 (0.40) ADORA3ADORA1NOS1NOS2GSK3B
SCHEMBL3949234 0.79 TSPO (0.38) ADORA3ADORA1
SCHEMBL3952077 0.78 MAPT (0.38) ADORA3ADORA1
SCHEMBL3952234 0.78 ADORA3 (0.36) ADORA3ADORA1
SCHEMBL3949356 0.78 ADORA3 (0.39) PDE4APDE4BPDE4CPDE4DADORA3
SCHEMBL3948904 0.78 PDK2 (0.37) ADORA3ADORA1
SCHEMBL30633389 0.78 ADORA3 (0.39) PDE4APDE4BPDE4CPDE4DADORA3
SCHEMBL3957784 0.77 ADORA2B (0.35) ADORA3ADORA1NOS1NOS2
SCHEMBL3951850 0.77 JAK3 (0.40) ADORA3ADORA1NOS1NOS2
SCHEMBL3950073 0.77 ADORA3 (0.34) ADORA3ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009029592-A1 HETEROBICYCLIC-SUBSTITUTED QUINOLONES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2009-03-05 — — WO disclosed
Send feedback